IP Library Granted Patent US 10,919,900
Granted Patent B2
US 10,919,900 · App. 16/570,045 · Granted Feb 16, 2021

Aryl hydrocarbon receptor antagonists and uses thereof

Inventor: Arthur Glenn Romero (Chesterfield, MO)
Assignee: Magenta Therapeutics Inc.
C07D487/04A61K35/28C07D471/04C07D519/00C12N5/0647A61K2035/124C12N2501/999Y02A50/401Y02A50/414
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,919,900
App. No.
16/570,045
Granted
Feb 16, 2021
Kind
B2
Abstract

The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.

Claims (59)

1. A method of producing an expanded population of hematopoietic stem cells ex vivo, comprising contacting a population of hematopoietic stem cells with a compound represented by formula (I) or (II):

wherein L is selected from the group consisting of —NR 7a (CR 8a R 8b ) n —, —O(CR 8a R 8b ) n —, —C(O)(CR 8a R 8b ) n —, —C(S)(CR 8a R 8b ) n —, —S(O) 0-2 (CR 8a R 8b ) n —, —(CR 8a R 8b ) n —, —NR 7a C(O)(CR 8a R 8b ) n —, —NR 7a C(S)(CR 8a R 8b ) n —, —OC(O)(CR 8a R 8b ) n —, —OC(S)(CR 8a R 8b ) n —, —C(O)NR 7a (CR 8a R 8b ) n —, —C(S)NR 7a (CR 8a R 8b ) n —, —C(O)O(CR 8a R 8b ) n —, —C(S)O(CR 8a R 8b ) n —, —S(O) 2 NR 7a (CR 8a R 8b ) n —, —NR 7a S(O) 2 (CR 8a R 8b ) n —, —NR 7a C(O)NR 7b (CR 8a R 8b ) n —, and —NR 7a C(O)O(CR 8a R 8b ) n —, wherein R 7a , R 7b , R 8a , and R 8b are each independently selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl, and each n is independently an integer from 2 to 6;

R 1 is selected from the group consisting of —S(O) 2 NR 9a R 9b , —NR 9a C(O)R 9b , —NR 9a C(S)R 9b , —NR 9a C(O)NR 9b R 9c , —C(O)R 9a , —C(S)R 9a , —S(O) 0-2 R 9a , —C(O)OR 9a , —C(S)OR 9a , —C(O)NR 9a R 9b , —C(S)NR 9a R 9b , —NR 9a S(O) 2 R 9b , —NR 9a C(O)OR 9b , —OC(O)CR 9a R 9b R 9c , —OC(S)CR 9a R 9b R 9c , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl, wherein R 9a , R 9b , and R 9c are each independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;

R 2 is selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl;

R 3 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;

R 4 is selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl;

R 5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; and

R 6 is selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;

or a salt thereof.

2. The method of claim 1 , wherein said compound is represented by formula (I-e) or (II-e)

wherein A is an optionally substituted ring system selected from the group consisting of phenyl, 1H-indol-2-yl, 1H-indol-3-yl, thiophen-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 1H-1,2,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl, 2-oxoimidazolidin-1-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, and 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl, wherein the phenyl, 1H-indol-2-yl, 1H-indol-3-yl, thiophen-3-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 1H-1,2,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl, 2-oxoimidazolidin-1-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, or 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl is optionally substituted with from 1 to 3 substituents independently selected from the group consisting of cyano, hydroxy, C1-4 alkyl, C1-4 alkoxy, halo, halo-substituted-C1-4 alkyl, halo-substituted-C1-4 alkoxy, amino, —O(CH 2 ) 2 NR 10a R 10b , —S(O) 2 NR 10a R 10b , —OS(O) 2 NR 10a R 10b , and —NR 10a S(O) 2 R 10b , wherein R 10a and R 10b are each independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;

B is an optionally substituted ring system selected from the group consisting of thiophen-2-yl, thiophen-3-yl, furan-3-yl, 1H-benzo[d]imidazol-1-yl, isoquinolin-4-yl, 1H-imidazo[4,5-b]pyridin-1-yl, imidazo[1,2-a]pyridin-3-yl, benzo[b]thiophen-3-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 1H-imidazol-1-yl, pyrazin-2-yl, pyridazin-4-yl, 1H-pyrrol-2-yl and thiazol-5-yl, wherein the thiophen-2-yl, thiophen-3-yl, furan-3-yl, 1H-benzo[d]imidazol-1-yl, isoquinolin-4-yl, 1H-imidazo[4,5-b]pyridin-1-yl, benzo[b]thiophen-3-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 1H-imidazol-1-yl, pyrazin-2-yl, pyridazin-4-yl, 1H-pyrrol-2-yl, or thiazol-5-yl is optionally substituted with from 1 to 3 substituents independently selected from the group consisting of cyano, hydroxy, C 1 -4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 alkoxy, halo, halo-substituted-C1-4 alkyl, halo-substituted-C1-4 alkoxy, amino, —C(O)R 11a , —S(O) 0-2 R 11a , —C(O)OR 11a , and —C(O)NR 11a R 11b , wherein R 11a and R 11b are each independently selected from the group consisting of hydrogen and C1-4 alkyl; and

R 5 is selected from the group consisting of C1-10 alkyl, prop-1-en-2-yl, cyclohexyl, cyclopropyl, 2-(2-oxopyrrolidin-1-yl)ethyl, oxetan-2-yl, oxetan-3-yl, benzhydryl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H-pyran-3-yl, phenyl, tetrahydrofuran-3-yl, benzyl, (4-pentylphenyl)(phenyl)methyl, and 1-(1-(2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)-1H-1,2,3-triazol-4-yl)ethyl, wherein the C1-10 alkyl, prop-1-en-2-yl, cyclohexyl, cyclopropyl, 2-(2-oxopyrrolidin-1-yl)ethyl, oxetan-2-yl, oxetan-3-yl, benzhydryl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H-pyran-3-yl, phenyl, tetrahydrofuran-3-yl, benzyl, (4-pentylphenyl)(phenyl)methyl, or 1-(1-(2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)-1H-1,2,3-triazol-4-yl)ethyl is optionally substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxy, C1-4 alkyl, and halo-substituted-C1-4alkyl, or R 5 is selected from the group consisting of (i), (ii), (iii), (iv), and (v)

wherein n is an integer from 1 to 6, m is an integer from 0 to 6, p is an integer from 0 to 5, and each R is independently selected from the group consisting of cyano, hydroxy, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 alkoxy, halo, halo-substituted-C1-4 alkyl, halo-substituted-C1-4 alkoxy, amino, —C(O)R 12a , —S(O) 0-2 R 12a , —C(O)OR 12a , and —C(O)NR 12a R 11b , and wherein R 12a and R 12b are each independently selected from the group consisting of hydrogen and C1-4 alkyl;

or a salt thereof.

3. The method of claim 1 , wherein said compound is represented by formula (I-f), (II-f), (I-g), or (II-g)

wherein A is an optionally substituted ring system selected from the group consisting of phenol-4-yl and 1H-indol-3-yl;

q is an integer from 0 to 4;

each Z is independently a substituent selected from the group consisting of C1-4 alkyl, halo, halo-substituted-C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 alkoxy, cyano, amino, C(O)R 11a , —S(O) 0-2 R 11a , —C(O)OR 11a , and —C(O)NR 11a R 11b , wherein R 11a and R 11b are each independently selected from the group consisting of hydrogen and C1-4 alkyl; and

R 5 is selected from the group consisting of isopropyl, methyl, ethyl, prop-1-en-2-yl, isobutyl, cyclohexyl, sec-butyl, (S)-sec-butyl, (R)-sec-butyl, 1-hydroxypropan-2-yl, (S)-1-hydroxypropan-2-yl, (R)-1-hydroxypropan-2-yl, and nonan-2-yl, or R 5 is selected from the group consisting of (i), (ii), (iii), (iv), and (v)

wherein n is an integer from 1 to 6, m is an integer from 0 to 6, p is an integer from 0 to 5, and each R is independently selected from the group consisting of cyano, hydroxy, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 alkoxy, halo, halo-substituted-C1-4 alkyl, halo-substituted-C1-4 alkoxy, amino, —C(O)R 12a , —S(O) 0-2 R 12a , —C(O)OR 12a , and —C(O)NR 12a R 12b , and wherein R 12a and R 11b are each independently selected from the group consisting of hydrogen and C1-4 alkyl;

or a salt thereof.

4. The method of claim 1 , wherein said compound is represented by-formula (I-h), (II-h), (I-i), (II-i), (I-j), (II-j), (I-k), or (II-k)

wherein A is an optionally substituted ring system selected from the group consisting of phenol-4-yl and 1H-indol-3-yl;

q is an integer from 0 to 4;

r is 0 or 1;

W and V are each independently a substituent selected from the group consisting of C1-4 alkyl, halo, halo-substituted-C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 alkoxy, cyano, amino, C(O)R 11a , —S(O) 0-2 R 11a , —C(O)OR 11a , and —C(O)NR 11a R 11b wherein R 11a and R 11b are each independently selected from the group consisting of hydrogen and C1-4 alkyl; and

R 5 is selected from the group consisting of C1-10 alkyl, prop-1-en-2-yl, cyclohexyl, cyclopropyl, 2-(2-oxopyrrolidin-1-yl)ethyl, oxetan-2-yl, oxetan-3-yl, benzhydryl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H-pyran-3-yl, phenyl, tetrahydrofuran-3-yl, benzyl, (4-pentylphenyl)(phenyl)methyl, and 1-(1-(2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)-1H-1,2,3-triazol-4-yl)ethyl, wherein the C1-10 alkyl, prop-1-en-2-yl, cyclohexyl, cyclopropyl, 2-(2-oxopyrrolidin-1-yl)ethyl, oxetan-2-yl, oxetan-3-yl, benzhydryl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H-pyran-3-yl, phenyl, tetrahydrofuran-3-yl, benzyl, (4-pentylphenyl)(phenyl)methyl, and 1-(1-(2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)-1H-1,2,3-triazol-4-yl)ethyl is optionally substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxy, C1-4 alkyl, and halo-substituted-C1-4alkyl, or R 5 is selected from the group consisting of (i), (ii), (iii), (iv), and (v)

wherein n is an integer from 1 to 6, m is an integer from 0 to 6, p is an integer from 0 to 5, and each R is independently selected from the group consisting of cyano, hydroxy, C 1 -4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 alkoxy, halo, halo-substituted-C1-4 alkyl, halo-substituted-C1-4 alkoxy, amino, —C(O)R 12a , —S(O) 0-2 R 12a , —C(O)OR 12a , and —C(O)NR 12a R 11b , and wherein R 12a and R 12b are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;

or a salt thereof.

5. The method of claim 3 , wherein said compound is represented by formula (II-f)

wherein A is an optionally substituted ring system selected from the group consisting of phenol-4-yl and 1H-indol-3-yl;

q is an integer from 0 to 4;

each Z is independently a substituent selected from the group consisting of C1-4 alkyl, halo, halo-substituted-C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 alkoxy, cyano, amino, C(O)R 11a , —S(O) 0-2 R 11a , —C(O)OR 11a , and —C(O)NR 11a R 11b , wherein R 11a and R 11b are each independently selected from the group consisting of hydrogen and C1-4 alkyl; and

R 5 is selected from the group consisting of isopropyl, methyl, ethyl, prop-1-en-2-yl, isobutyl, cyclohexyl, sec-butyl, (S)-sec-butyl, (R)-sec-butyl, 1-hydroxypropan-2-yl, (S)-1-hydroxypropan-2-yl, (R)-1-hydroxypropan-2-yl, and nonan-2-yl, or R 5 is selected from the group consisting of (i), (ii), (iii), (iv), and (v)

wherein n is an integer from 1 to 6, m is an integer from 0 to 6, p is an integer from 0 to 5, and each R is independently selected from the group consisting of cyano, hydroxy, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 alkoxy, halo, halo-substituted-C1-4 alkyl, halo-substituted-C1-4 alkoxy, amino, —C(O)R 12a , —S(O) 0-2 R 12a , —C(O)OR 12a , and —C(O)NR 12a R 11b , and wherein R 12a and R 12b are each independently selected from the group consisting of hydrogen and C1-4 alkyl;

or a salt thereof.

6. The method of claim 3 , wherein said compound is represented by formula (II-g)

wherein A is an optionally substituted ring system selected from the group consisting of phenol-4-yl and 1H-indol-3-yl;

Z is a substituent selected from the group consisting of C1-4 alkyl, halo, halo-substituted-C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 alkoxy, cyano, amino, C(O)R 11a , —S(O) 0-2 R 11a , —C(O)OR 11a , and —C(O)NR 11a R 11b , wherein R 11a and R 11b are each independently selected from the group consisting of hydrogen and C1-4 alkyl; and

R 5 is selected from the group consisting of isopropyl, methyl, ethyl, prop-1-en-2-yl, isobutyl, cyclohexyl, sec-butyl, (S)-sec-butyl, (R)-sec-butyl, 1-hydroxypropan-2-yl, (S)-1-hydroxypropan-2-yl, (R)-1-hydroxypropan-2-yl, and nonan-2-yl, or R 5 is selected from the group consisting of (i), (ii), (iii), (iv), and (v)

wherein n is an integer from 1 to 6, m is an integer from 0 to 6, p is an integer from 0 to 5, and each R is independently selected from the group consisting of cyano, hydroxy, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 alkoxy, halo, halo-substituted-C1-4 alkyl, halo-substituted-C1-4 alkoxy, amino, —C(O)R 12a , —S(O) 0-2 R 12a , —C(O)OR 12a , and —C(O)NR 12a R 12b , and wherein R 12a and R 12b are each independently selected from the group consisting of hydrogen and C1-4 alkyl;

or a salt thereof.

7. The method of claim 5 , wherein A is phenol-4-yl.

8. The method of claim 5 , wherein A is 1H-indol-3-yl.

9. The method of claim 5 , wherein R 5 is selected from the group consisting of isopropyl, methyl, ethyl, isobutyl, cyclohexyl, hydroxypropan-2-yl, sec-butyl, 3-ethoxy-1-methylpropyl, 1-methoxy-4-pentyl, and 1-methoxy-3-butyl.

10. The method of claim 5 , wherein each Z is independently selected from the group consisting of methyl, ethynyl, cyclopropyl, fluoro, chloro, trifluoromethyl, and cyano.

11. The method of claim 6 , wherein R 5 is selected from the group consisting of isopropyl, methyl, ethyl, isobutyl, cyclohexyl, hydroxypropan-2-yl, sec-butyl, 3-ethoxy-1-methylpropyl, 1-methoxy-4-pentyl, and 1-methoxy-3-butyl.

12. The method of claim 6 , wherein Z is selected from the group consisting of methyl, ethynyl, cyclopropyl, fluoro, chloro, trifluoromethyl, and cyano.

13. The method of claim 6 , wherein

A is 1H-indol-3-yl;

R 5 is selected from the group consisting of isopropyl, methyl, ethyl, isobutyl, cyclohexyl, hydroxypropan-2-yl, sec-butyl, 3-ethoxy-1-methylpropyl, 1-methoxy-4-pentyl, and 1-methoxy-3-butyl; and

Z is selected from the group consisting of methyl, ethynyl, cyclopropyl, fluoro, chloro, trifluoromethyl, and cyano.

14. The method of claim 1 , wherein said compound is selected from the group consisting of

and salts thereof.

15. The method of claim 5 , wherein said compound is a compound selected from the group consisting of

and salts thereof.

16. The method of claim 3 , wherein said compound is selected from the group consisting of

and salts thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2023
From: MAGENTA THERAPEUTICS, INC.
To: EDIGENE BIOTECHNOLOGY, INC.
Reel/Frame 064224/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2019
From: GONCALVES, KEVIN A.
To: MAGENTA THERAPEUTICS INC.
Reel/Frame 050370/0236 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2019
From: ROMERO, ARTHUR GLENN
To: PHARMA-VATION CONSULTING, LLC
Reel/Frame 050370/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2019
From: PHARMA-VATION CONSULTING, LLC
To: MAGENTA THERAPEUTICS INC.
Reel/Frame 050370/0263 →
Continuity (5)
Continuation 15951585 · Apr 12, 2018
Provisional Application 62625896 · Feb 2, 2018
Provisional Application 62613382 · Jan 3, 2018
Provisional Application 62484692 · Apr 12, 2017
Related Publication 20200123161A1 · Apr 23, 2020